BRISBANE, Calif., June 22 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today that Dan Welch, President and CEO of InterMune, will present a corporate overview at the Jefferies Life Sciences Conference in New York City on June 28, 2006 at 9:30am EDT. To access the live audio webcast, log on to the investor relations page of InterMune’s website at www.intermune.com. The Company recommends logging on 15 minutes early in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes two Phase III programs evaluating possible therapeutic candidates for treatment of patients with IPF: the INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the lead HCV protease inhibitor compound, ITMN-191, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to anticipated future financial results and product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading ‘Risk Factors’ in InterMune’s annual report on Form 10-K filed with the SEC on March 13, 2006 (the “Form 10-K”) and updates included in the most recent Form 10-Q filed with the SEC on May 9, 2006 (the “Form 10-Q”), and other periodic reports filed with the SEC.
InterMune, Inc.
CONTACT: investors, Investor Relations Dept of InterMune, Inc.,+1-415-466-2242, or ir@intermune.com; or media, Pam Lord of Porter NovelliLife Sciences, +1-858-527-3494, or plord@pnlifesciences.com, for InterMune
Web site: http://www.intermune.com//
